Global Alzheimer's Disease Therapeutics and Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030
1 Market Overview
- 1.1 Product Overview and Scope of Alzheimer's Disease Therapeutics and Diagnostics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Alzheimer's Disease Therapeutics and Diagnostics by Type
- 1.3.1 Overview: Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption Value Market Share by Type in 2023
- 1.3.3 Biomarkers
- 1.3.4 Cholinesterase inhibitors
- 1.3.5 NMDA receptor antagonists
- 1.3.6 Brain imaging
- 1.3.7 Blood tests
- 1.4 Global Alzheimer's Disease Therapeutics and Diagnostics Market by Application
- 1.4.1 Overview: Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Drugs Market
- 1.4.3 Diagnostics Market
- 1.5 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size & Forecast
- 1.6 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast by Region
- 1.6.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region, (2019-2030)
- 1.6.3 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size and Prospect (2019-2030)
- 1.6.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size and Prospect (2019-2030)
- 1.6.6 South America Alzheimer's Disease Therapeutics and Diagnostics Market Size and Prospect (2019-2030)
- 1.6.7 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Namenda
- 2.1.1 Namenda Details
- 2.1.2 Namenda Major Business
- 2.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.1.4 Namenda Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Namenda Recent Developments and Future Plans
- 2.2 Aricept
- 2.2.1 Aricept Details
- 2.2.2 Aricept Major Business
- 2.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.2.4 Aricept Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Aricept Recent Developments and Future Plans
- 2.3 Exelon
- 2.3.1 Exelon Details
- 2.3.2 Exelon Major Business
- 2.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.3.4 Exelon Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Exelon Recent Developments and Future Plans
- 2.4 Solanezumab
- 2.4.1 Solanezumab Details
- 2.4.2 Solanezumab Major Business
- 2.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.4.4 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Solanezumab Recent Developments and Future Plans
- 2.5 Gantenerumab
- 2.5.1 Gantenerumab Details
- 2.5.2 Gantenerumab Major Business
- 2.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.5.4 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Gantenerumab Recent Developments and Future Plans
- 2.6 Verubecestat
- 2.6.1 Verubecestat Details
- 2.6.2 Verubecestat Major Business
- 2.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.6.4 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Verubecestat Recent Developments and Future Plans
- 2.7 Pfizer
- 2.7.1 Pfizer Details
- 2.7.2 Pfizer Major Business
- 2.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.7.4 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Pfizer Recent Developments and Future Plans
- 2.8 Eisai
- 2.8.1 Eisai Details
- 2.8.2 Eisai Major Business
- 2.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.8.4 Eisai Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Eisai Recent Developments and Future Plans
- 2.9 Actavis
- 2.9.1 Actavis Details
- 2.9.2 Actavis Major Business
- 2.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.9.4 Actavis Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 Actavis Recent Developments and Future Plans
- 2.10 Lundbeck
- 2.10.1 Lundbeck Details
- 2.10.2 Lundbeck Major Business
- 2.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.10.4 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Lundbeck Recent Developments and Future Plans
- 2.11 Daiichi Sankyo
- 2.11.1 Daiichi Sankyo Details
- 2.11.2 Daiichi Sankyo Major Business
- 2.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.11.4 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 Daiichi Sankyo Recent Developments and Future Plans
- 2.12 Novartis
- 2.12.1 Novartis Details
- 2.12.2 Novartis Major Business
- 2.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.12.4 Novartis Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Novartis Recent Developments and Future Plans
- 2.13 TauRx
- 2.13.1 TauRx Details
- 2.13.2 TauRx Major Business
- 2.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Product and Solutions
- 2.13.4 TauRx Alzheimer's Disease Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.13.5 TauRx Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Alzheimer's Disease Therapeutics and Diagnostics by Company Revenue
- 3.2.2 Top 3 Alzheimer's Disease Therapeutics and Diagnostics Players Market Share in 2023
- 3.2.3 Top 6 Alzheimer's Disease Therapeutics and Diagnostics Players Market Share in 2023
- 3.3 Alzheimer's Disease Therapeutics and Diagnostics Market: Overall Company Footprint Analysis
- 3.3.1 Alzheimer's Disease Therapeutics and Diagnostics Market: Region Footprint
- 3.3.2 Alzheimer's Disease Therapeutics and Diagnostics Market: Company Product Type Footprint
- 3.3.3 Alzheimer's Disease Therapeutics and Diagnostics Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Alzheimer's Disease Therapeutics and Diagnostics Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Type (2019-2030)
- 6.2 North America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Application (2019-2030)
- 6.3 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country
- 6.3.1 North America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Country (2019-2030)
- 6.3.2 United States Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 6.3.3 Canada Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Type (2019-2030)
- 7.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Application (2019-2030)
- 7.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country
- 7.3.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Country (2019-2030)
- 7.3.2 Germany Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 7.3.3 France Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 7.3.5 Russia Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 7.3.6 Italy Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region
- 8.3.1 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Region (2019-2030)
- 8.3.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 8.3.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 8.3.5 India Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 8.3.7 Australia Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Type (2019-2030)
- 9.2 South America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Application (2019-2030)
- 9.3 South America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country
- 9.3.1 South America Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country
- 10.3.1 Middle East & Africa Alzheimer's Disease Therapeutics and Diagnostics Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
- 10.3.4 UAE Alzheimer's Disease Therapeutics and Diagnostics Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Alzheimer's Disease Therapeutics and Diagnostics Market Drivers
- 11.2 Alzheimer's Disease Therapeutics and Diagnostics Market Restraints
- 11.3 Alzheimer's Disease Therapeutics and Diagnostics Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Alzheimer's Disease Therapeutics and Diagnostics Industry Chain
- 12.2 Alzheimer's Disease Therapeutics and Diagnostics Upstream Analysis
- 12.3 Alzheimer's Disease Therapeutics and Diagnostics Midstream Analysis
- 12.4 Alzheimer's Disease Therapeutics and Diagnostics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Alzheimer's Disease Therapeutics and Diagnostics market size was valued at USD 3722.7 million in 2023 and is forecast to a readjusted size of USD 4113.3 million by 2030 with a CAGR of 1.4% during review period.
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Alzheimer's Disease Therapeutics and Diagnostics industry chain, the market status of Drugs Market (Biomarkers, Cholinesterase inhibitors), Diagnostics Market (Biomarkers, Cholinesterase inhibitors), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Alzheimer's Disease Therapeutics and Diagnostics.
Regionally, the report analyzes the Alzheimer's Disease Therapeutics and Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Alzheimer's Disease Therapeutics and Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Alzheimer's Disease Therapeutics and Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Alzheimer's Disease Therapeutics and Diagnostics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Biomarkers, Cholinesterase inhibitors).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Alzheimer's Disease Therapeutics and Diagnostics market.
Regional Analysis: The report involves examining the Alzheimer's Disease Therapeutics and Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Alzheimer's Disease Therapeutics and Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Alzheimer's Disease Therapeutics and Diagnostics:
Company Analysis: Report covers individual Alzheimer's Disease Therapeutics and Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Alzheimer's Disease Therapeutics and Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Drugs Market, Diagnostics Market).
Technology Analysis: Report covers specific technologies relevant to Alzheimer's Disease Therapeutics and Diagnostics. It assesses the current state, advancements, and potential future developments in Alzheimer's Disease Therapeutics and Diagnostics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Alzheimer's Disease Therapeutics and Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Alzheimer's Disease Therapeutics and Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Market segment by Application
Drugs Market
Diagnostics Market
Market segment by players, this report covers
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Alzheimer's Disease Therapeutics and Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Alzheimer's Disease Therapeutics and Diagnostics, with revenue, gross margin and global market share of Alzheimer's Disease Therapeutics and Diagnostics from 2019 to 2024.
Chapter 3, the Alzheimer's Disease Therapeutics and Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Alzheimer's Disease Therapeutics and Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Alzheimer's Disease Therapeutics and Diagnostics.
Chapter 13, to describe Alzheimer's Disease Therapeutics and Diagnostics research findings and conclusion.